	Dec 22, 2006	Protox Second Closing Increases Private Placement to $10 Million
	Nov 29, 2006	Protox Releases Q3 Financial Results and Company Highlights
	Nov 29, 2006	Protox Therapeutics Completes $9.1 Million Private Placement
	Nov 21, 2006	Protox Presents PORxin™ Data at International Cancer Conference
	Oct 25, 2006	Protox Announces Private Placement
	Oct 24, 2006	M. D. Anderson Cancer Center Participates in Protox Prostate Cancer Study
	Oct 11, 2006	Protox Receives Approval from Health Canada for BPH Clinical Trial
	Sep 21, 2006	Protox Files Clinical Trial Application With Health Canada For BPH
	Aug 29, 2006	Protox Releases Q2, 2006 Financial Results and Company Highlights
	Aug 24, 2006	Protox Announces New Director of Investor Relations and Corporate Communications
	Aug 10, 2006	Protox Advances Phase I Prostate Cancer Study and Planned BPH Clinical Trial
	Aug 1, 2006	Protox Announces New Institutional Investor
	July 20, 2006	Protox Acquires Phase II Cancer Program from Neurocrine and U.S. Public Health Service
	June 23, 2006	Protox Therapeutics Retains Leading Investor Relations Firm
	June 19, 2006	Protox Announces Changes to Board of Directors
	June 15, 2006	Protox Therapeutics to Present at London Biotech Investment Forum
	June 14, 2006	Protox Strengthens Intellectual Property Portfolio with New Patent Application
	June 7, 2006	Protox Therapeutics to Present at Technology and Life Sciences Forum
	May 29, 2006	Protox Releases Q1, 2006 Financial Statements; Prostate Cancer Trial on Track
	May 2, 2006	Protox Successfully Doses First Patient in Prostate Cancer Trial using PRX302
	May 1, 2006	Protox Therapeutics to Present at BioFinance 2006 Conference
	Apr 28, 2006	Protox Releases Financial Statements and Reviews Achievements for 2005
	Apr 7, 2006	Protox Therapeutics Grants Stock Options
	Apr 3, 2006	Protox Therapeutics Announces Presentation of Data at Leading Cancer Research Conference
	Mar 27, 2006	Protox Therapeutics to be featured on CEO Clips on The Biography Channel
	Mar 16, 2006	Protox Therapeutics to present at Invest Northwest Conference
	Mar 8, 2006	Protox Therapeutics conference call notification
	Jan 16, 2006	Protox receives FDA clearance to beginPhase I prostate cancer trial

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

Stock Quote

	LAST TRADE:	$0.39
	TRADE TIME:	3:53PM EST
	CHANGE:	$0.00 (0.00%)
	PREV CLOSE:	$0.39
	OPEN:	$0.39
	BID:	$0.385
	ASK:	$0.39